Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 16, 2025 07:00 ET | Source: Endure Biotherapeutics, Inc.

National PKU Alliance Grant Advances Engineered Native Bacteria Candidate for Phenylketonuria (PKU)

San Diego, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Endure Biotherapeutics, Inc. (Endure Bio®), a pioneer in engineered engraftable microbial therapeutics, today announced that its founding discovery...
October 09, 2025 10:01 ET | Source: Optime Care

Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)

Optime Care Terminates Distributor Agreement for Korlym® (mifepristone)
August 12, 2025 07:00 ET | Source: Endure Biotherapeutics, Inc.

Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis

San Diego, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous...
April 08, 2025 10:00 ET | Source: AscellaHealth, LLC

AscellaHealth Showcases Rare Disease Expertise and Comprehensive Specialty Pharmaceutical Solutions at World Orphan Drug Congress USA 2025

AscellaHealth Highlights Rare Disease Capabilities and End-to-End Specialty Pharmaceutical Solutions at World Orphan Drug Congress USA 2025
March 18, 2025 07:30 ET | Source: FACT.MR

Rare Neurological Disease Treatment Market to Reach USD 115.8 Billion by 2035, Growing at 9.7% CAGR | Fact.MR Report

Rockville, MD, March 18, 2025 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the The global rare neurological disease treatment market was valued...
January 10, 2025 08:00 ET | Source: World Orphan Drug Alliance (WODA)

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering.
October 22, 2024 10:00 ET | Source: AscellaHealth, LLC

AscellaHealth Releases Q3 2024 Specialty & Rare Pipeline Digest™: FDA-Approved Biosimilars Outpaces Cell and Gene Therapy Amid Complex Regulatory Challenges

BERWYN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today released its latest...
October 17, 2024 06:00 ET | Source: AscellaHealth, LLC; CHAPPER healthcare

AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services

AscellaHealth Announces Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services
September 04, 2024 08:00 ET | Source: World Orphan Drug Alliance (WODA); Oncopeptides AB, Veld Pharmaceuticals GmbH, Slavpharma GmbH

Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients

Oncopeptides expands on WODA partnership with addition of Africa and Eurasia to provide Pepaxti to Patients
April 08, 2024 07:30 ET | Source: World Orphan Drug Alliance (WODA)

World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent

World Orphan Drug Alliance Expands to Japan & South Korea and the African Subcontinent